Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC
© Madoiwa; licensee BioMed Central. 2015
Received: 27 December 2014
Accepted: 29 January 2015
Published: 19 February 2015
Endothelial cells are highly active, sensing and responding to signals from extracellular environments. They act as gatekeepers, mediating the recruitment and extravasation of proinflammatory leukocytes to the sites of tissue damage or infection. Endothelial cells participate in fibrinolysis by secreting tissue-type plasminogen activator, which converts plasminogen to active enzyme plasmin through constitutive and regulated pathways. Fibrinolysis systems and inflammation are tightly linked, as both responses are major host defense systems against both healing processes of tissue repair as well as pathogenic microorganisms. Endothelial cell dysfunction is one of the early signs of systemic inflammation, and it is a trigger of multiple organ failure in sepsis. The marked increase in plasminogen activator inhibitor-1 level causes fibrinolytic shutdown in endotoxemia or sepsis and is one of the most important predictors of multiple organ dysfunction during sepsis-induced disseminated intravascular coagulation (DIC). Leukocytes exhibit the first-line response to microorganisms. Leukocyte-derived elastase degrades cross-linked fibrin to yield molecular species distinct from those generated by plasmin. The alternative systems for fibrinolysis that interact with the plasminogen activator-plasmin systems may play crucial roles in the lysis of fibrin clots in sepsis-induced DIC.
The vascular endothelium is highly dynamic and exhibits functional complexity. It performs its essential function of regulating systemic blood flow by finely tuning the diameter of blood vessels and regulates vascular tone by releasing vasodilators including nitric oxide and prostaglandin I2 as well as vasoconstrictors such as endothelin and platelet-activating factor. Uncontrolled and spreading systemic inflammatory responses to microbial infections play critical roles in the pathogenesis of sepsis. Under these conditions, leukocyte accumulation damages the endothelial cells and heightens permeability, leading to tissue edema.
The systemic inflammatory response occasionally causes abnormalities related to blood coagulation and fibrinolysis, ranging from subtle activation of coagulation and fibrinolysis systems to disseminated intravascular coagulation (DIC), which is characterized by simultaneous widespread microvascular thrombosis and profuse hemorrhaging . However, the pathophysiology of sepsis-induced DIC is extremely complex and under extensive investigation . The key event underlying life-threatening complications is the overwhelming host inflammatory response to the infectious microorganism, leading to the overexpression of inflammatory mediators . This article briefly summarizes the current knowledge of the pathogenesis of DIC focusing on vascular endothelial cells and the plasminogen activator-plasmin systems in sepsis.
Endothelial cell functions in physiological states
Endothelial cells act as gatekeepers to mediate the recruitment and extravasation of proinflammatory leukocytes to the sites of tissue damage or infection. There is a multistep cascade in leukocyte trafficking, including rolling, firm adhesion, and transmigration. Each step is enhanced by the upregulation of adhesion molecules on the surface of endothelial cells and the expression of chemokines. In brief, rolling of leukocytes on the endothelial cells is promoted by binding between the endothelial E-selectin and P-selectin with specific leukocyte ligands, CD44, E-selectin ligand-1 (ESL-1), and β2 integrins. Firm adhesion and resistance to dislodgement by fluid shear stress is promoted by the bindings of the endothelial cell protein vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 with leukocyte integrins . The leukocytes then transmigrate between endothelial cells into extravascular tissues, which requires the coordinated redistribution of lymphocyte function-associated antigen-1 (LFA-1) and endothelial cell ICAM-1.
Fibrinolysis under normal physiological conditions
Following the activation of blood coagulation systems, fibrin generation and tissue hypoxia stimulate an increase in tPA secretion from endothelial cells, which initiates and accelerates the conversion of plasminogen to active enzyme plasmin . Plasmin is a serine protease that hydrolyzes cross-linked fibrin, resulting in the release of a variety of complexes made up degradation products. The DD/E fragment is the smallest complex, consisting of two fragment D moieties and a non-covalently bound fragment E. DD/E is held together by uncleaved coiled coils, with larger forms representing longitudinally associated strings of DD/E.
Several types of cells, including vascular endothelial cells, produce plasminogen activator inhibitor-1 (PAI-1), which specifically regulates the initial phase of fibrinolysis by inhibiting plasminogen activators. PAI-1 efficiently inhibits tPA by rapid binding, forming a stable 1:1 complex. PAI-1 acts as an acute phase reactant, as its levels drastically increase during various inflammatory responses . α2-Plasmin inhibitor (α2-PI) is a physiological inhibitor of plasmin that regulates the late phase of fibrinolysis. α2-PI circulates in plasma at half the molar concentration of plasminogen. Thus, the α2-PI concentration is sufficient to neutralize plasmin under normal physiological conditions, where only small amounts of plasminogen are activated. α2-PI rapidly inhibits plasmin by irreversibly binding, forming an inactive complex with plasmin (plasmin-inhibitor complex; PIC). In addition, α2-PI inhibits the binding of plasminogen to fibrin molecules through competition for lysine binding sites, which is a unique regulatory phenomenon of fibrinolysis. During stable clot formation, α2-PI is cross-linked to fibrin by factor XIIIa, and α2-PI-bound fibrin is resistant to degradation by plasmin. TAFI is a carboxypeptidase B-like proenzyme that is converted to active enzyme TAFIa by thrombin. The endothelial cell receptor thrombomodulin stimulates the thrombin-mediated TAFI activation greater than 1,000-fold . TAFIa slowly inhibits the fibrinolytic processes by removing carboxyl-terminal lysine residues from fibrin molecules. This action is inhibitory because carboxyl-terminal lysine residues are important stimulators, serving as binding sites for tPA and plasminogen, as well as plasmin.
Inflammation and endothelial cells
Blood coagulation and inflammation are tightly linked, as both responses are major host defense systems of the healing process of damaged tissue repair and against the presence of pathogenic microorganisms . Tissue damage and exposure to proinflammatory stimuli shift the balance of the endothelial function toward a procoagulant phenotype . Inflammation is characterized by increased permeability of the vascular endothelium, causing leakage of blood components and extravasation of immune cells, including macrophages and dendritic cells . The vascular endothelial cells contribute to innate immunity as nonprofessional effectors. These cells recognize the presence of microorganisms through their toll-like receptors (TLRs), which are responsible for recognizing structures conserved among microbial species, pathogen-associated molecular patterns (PAMPs). Sepsis is associated with a dysfunction of the host immune system response to invading pathogens . An excessive response to TLR ligands is known to induce lethal septic shock. TLRs are also capable of detecting endogenous molecules released from damaged cells, termed as damage-associated molecular patterns (DAMPs). Thus, stimulations of PAMPs or DAMPs through TLRs activate signaling pathways that depend mainly on MyD88 and TRIF, leading to the translocation of NF-κB and IRFs into the nucleus . The activation of these transcription factors induces the expression of type I interferons (IFNs) and proinflammatory cytokine genes such as tumor necrosis factor (TNF) and IL-6.
The coagulation serine proteases initiate proinflammatory or anti-inflammatory signaling through PARs, which are widely expressed on platelets, endothelial cells, and immune cells . In endothelial cells, responses to thrombin are mediated by PAR1, and responses to tissue factor/factor VIIa and factor Xa are mainly facilitated by PAR2 . PAR1 activation by thrombin stimulates Rho-dependent cytoskeletal responses involved in the permeability and migration of endothelial cells . Activation of endothelial surfaces by PAR1 promotes adhesion and rolling of leukocytes. The sphigosine 1-phosphate (S1P) is a downstream component of PAR1 signaling that plays a critical role in the amplification of the inflammation response, through the regulation of motility of dendritic cells onto lymph nodes during severe sepsis . Interestingly, activated protein C on EPCR elicits cytoprotective signals through the activation of PAR1, which is fundamentally different from activation by thrombin. The localized activation of PAR1 in caveolae by activated protein C on EPCR and transactivation of the S1P receptor are thought to be responsible for the anti-inflammatory and anti-apoptotic effects . Moreover, TAFIa promotes anti-inflammatory effects by inactivating the complement factors C5a and C3a on endothelial cells. In vivo studies demonstrated that TAFI deficiency exacerbated allergic inflammation and acute lung injury [27,28].
Dysfunction of endothelial cells in sepsis
Sepsis is a systemic inflammatory response syndrome (SIRS), occurring in patients with infection or injury. The dysfunction of vascular endothelial cells is one of the early signs of a systemic inflammation and is a trigger for multiple organ failure in sepsis . The clinical features of sepsis-induced DIC include widespread thrombosis in the microcirculation of different tissues, resulting in severe disruption of organ homeostasis. The development of DIC in septic patients has been found to be an independent predictor of mortality .
Endothelial cell dysfunction and regulation of blood coagulation
The vascular response against to inflammation is characterized by smooth muscle changes, inducing vascular dilation and endothelial cell contraction. These result in vascular leakage of proteins into extravascular spaces and tissues. The inflammatory provocations also promote the migration of leukocytes from the microvascular circulation into inflammatory sites by stimulating increased expression of adhesion molecules on the surface of endothelial cells, including selectins.
Antithrombin is the primary inhibitor of both thrombin and factor Xa and is markedly decreased in sepsis. This decrease is caused by the reduction in hepatic synthesis of the negative acute phase protein, consumption by formation of thrombin-antithrombin complexes, and degradation by proteases released from activated neutrophils . In addition, glycosaminoglycans including heparin sulfate, hyaluronic acid, and chondroitin sulfate form an endothelial surface layer, which contributes to the regulation of thrombin and factor Xa by inducing the allosteric activation of antithrombin III. Degradation of the endothelial surface layer has been implicated in the pathogenesis of systemic inflammation, and protection of glycosaminoglycans is a goal of resuscitation strategies for intensive care unit (ICU) patients . Much attention has been devoted to the role of thrombomodulin as a pivotal determinant of endothelial thrombo-resistance as well as a target for the resolution of vascular disorders in DIC. Suppression of endothelial thrombomodulin expression by TNF-α has been documented . Several studies have suggested that neutrophil-derived elastase and cathepsin G proteolytically cleave endothelial cell surface thrombomodulin. This increased thrombomodulin shedding is a potential causative element of vascular injury . An elevated thrombomodulin serum level is widely regarded as an important biomarker for endothelial dysfunction  and has been found to correlate with the severity of sepsis-induced DIC . In addition, the amino-terminal lectin-like domain of thrombomodulin plays a critical role in regulating inflammatory responses. This domain functions by inhibiting leukocyte adhesion onto endothelial cells and complement pathways and degrading proinflammatory high-mobility group box 1 protein . The therapeutic benefits of administering recombinant soluble thrombomodulin as a treatment for severe inflammatory disorders such as sepsis-induced DIC have been demonstrated in studies conducted in Japan .
Endothelial cell dysfunction and the fibrinolysis system
Transient activation of plasminogen activators-plasmin systems has been observed during the immediate posttraumatic period, which results in a state of shock with serious hemorrhaging . Less than 1 h after severe injury, catecholamine-induced endothelial damage, hypoxia, and ischemia may invoke a marked release of tPA from the endothelium into circulation resulting in the conversion of large amounts of plasminogen to plasmin . However, there is some controversy and conflicting data still surround the exact underlying pathophysiology. Following the 24–48 h after trauma, the inflammatory influences on coagulation favor a more prothrombotic tendency, where proinflammatory cytokines downregulate protein S, endothelial-based heparin sulfate proteoglycans, thrombomodulin, and endothelial protein C receptor.
Endothelial cell dysfunction and leukocyte elastase
The release of PAMPs during a microbial infection induces tissue macrophages to generate inflammatory cytokines, including TNF-α, IL-1, and IL-8. The localized activation of these cytokines contributes to host defenses by attracting activated leukocytes to the site of infection. However, the entry of inflammatory cytokines and PAMPs into blood circulation may lead to microvascular damage . Leukocytes are known to release enzymes with intrinsic proteolytic activity, including leukocyte elastase and cathepsin G, in a variety of clinical conditions. The subsequent scope of leukocyte elastase activity is mediated by endogenous inhibitors, predominantly α1-protease inhibitor [51,52]. Leukocyte elastase is a potent protease, as it cleaves nearly all connective tissue components, including elastin and a variety of proteoglycans. Interestingly, leukocyte elastase has two opposing roles in fibrinolysis . It promotes fibrinolytic functions by degrading fibrinogen and fibrin and inactivating PAI-1 . By contrast, leukocyte elastase has antifibrinolytic activities cleaving plasminogen activators and plasmin .
Microthrombi caused by endothelial injuries induce ischemia and cause damage to a variety of organs in sepsis-induced DIC. Multiple studies have implicated the proteases released from leukocytes to be involved in the progression of multiple organ injuries. A deficiency of ADAMTS13, also known as VWF-cleaving protease, leads to the presence of unusually large multimers. These are responsible for the aggregation of platelet formation of microthrombi in the circulatory system, which leads to typical thrombotic microangiopathies . Cleavage of ADAMTS13 by leukocyte elastase together with thrombin and plasmin cause a severe secondary ADAMTS13 deficiency, and there may be a clinical correlation with renal endothelial cells dysfunction in patients with sepsis-induced DIC .
Leukocytes exhibit the first line of response to microorganisms. Activated leukocytes and dying cells release histones (particularly histones H3 and H4) and may promote thrombus formation by inducing endothelial injury during sepsis . In addition, neutrophils stimulated by activated platelets release the neutrophil extracellular traps (NETs) containing histones, DNA, and leukocyte-derived proteases . Although NETs have a pivotal role in the suppression of pathogen dissemination and killing of microorganisms, they also induce tissue damage and thrombus formation [60,61].
It is clear that endothelial cell function, inflammatory mediators, and the associated crosstalk with blood coagulation and fibrinolysis systems are altered in sepsis-induced DIC and that significant heterogeneity exists in the host response against a microbial infection . Further research elucidating basal mechanisms at the cellular and molecular levels may bring clinicians closer to improving morbidity and mortality of patients with sepsis-induced DIC.
This work was partially supported by grants of SENSHIN Medical Research Foundation and Special Project Award from Bayer Hemophilia Award Program.
- Levi M, ten Cate H, van der Poll T, van Deventer SJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA. 1993;270:975–9.View ArticlePubMedGoogle Scholar
- Slofstra SH, Spek CA, ten Cate H. Disseminated intravascular coagulation. Hematol J. 2003;4:295–302.View ArticlePubMedGoogle Scholar
- Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290–5.View ArticlePubMedGoogle Scholar
- Michiels C. Endothelial cell functions. J Cell Physiol. 2003;196:430–43.View ArticlePubMedGoogle Scholar
- Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527–61.PubMedGoogle Scholar
- Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257:7944–7.PubMedGoogle Scholar
- Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603–8.View ArticlePubMedGoogle Scholar
- van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood. 1995;85:3510–7.PubMedGoogle Scholar
- Suzuki Y, Mogami H, Ihara H, Urano T. Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood. 2009;113:470–8.View ArticlePubMedGoogle Scholar
- Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, et al. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood. 2010;115:1319–30.View ArticlePubMed CentralPubMedGoogle Scholar
- O'Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. Blood. 2010;116:1136–46.View ArticlePubMedGoogle Scholar
- Surette AP, Madureira PA, Phipps KD, Miller VA, Svenningsson P, Waisman DM. Regulation of fibrinolysis by S100A10 in vivo. Blood. 2011;118:3172–81.View ArticlePubMedGoogle Scholar
- Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994–1004.View ArticlePubMedGoogle Scholar
- Madoiwa S, Someya T, Hironaka M, Kobayashi H, Ohmori T, Mimuro J, et al. Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. Thromb Res. 2007;119:229–40.View ArticlePubMedGoogle Scholar
- Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67:1033–6.View ArticlePubMedGoogle Scholar
- Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381–7.PubMedGoogle Scholar
- Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med. 1986;163:1260–6.View ArticlePubMedGoogle Scholar
- Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–35.View ArticlePubMedGoogle Scholar
- Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12:329–41.View ArticlePubMedGoogle Scholar
- Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–20.View ArticlePubMedGoogle Scholar
- Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ. 2007;335:879–83.View ArticlePubMed CentralPubMedGoogle Scholar
- Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258–64.View ArticlePubMedGoogle Scholar
- Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem. 2002;277:16081–7.View ArticlePubMedGoogle Scholar
- Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol Biol Cell. 1998;9:2639–53.View ArticlePubMed CentralPubMedGoogle Scholar
- Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature. 2008;452:654–8.View ArticlePubMedGoogle Scholar
- Russo A, Soh UJ, Paing MM, Arora P, Trejo J. Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci U S A. 2009;106:6393–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Fujiwara A, Taguchi O, Takagi T, D'Alessandro-Gabazza CN, Boveda-Ruiz D, Toda M, et al. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma. Lung. 2012;190:189–98.View ArticlePubMedGoogle Scholar
- Naito M, Taguchi O, Kobayashi T, Takagi T, D'Alessandro-Gabazza CN, Matsushima Y, et al. Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system. Am J Respir Cell Mol Biol. 2013;49:646–53.View ArticlePubMedGoogle Scholar
- Czabanka M, Peter C, Martin E, Walther A. Microcirculatory endothelial dysfunction during endotoxemia–insights into pathophysiology, pathologic mechanisms and clinical relevance. Curr Vasc Pharmacol. 2007;5:266–75.View ArticlePubMedGoogle Scholar
- Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis. 2006;17:445–51.View ArticlePubMedGoogle Scholar
- van der Poll T, Levi M, van Deventer SJ, ten Cate H, Haagmans BL, Biemond BJ, et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 1994;83:446–51.PubMedGoogle Scholar
- van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997;89:3727–34.PubMedGoogle Scholar
- van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:639–51.View ArticlePubMedGoogle Scholar
- Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170–5.PubMedGoogle Scholar
- Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125 Suppl 1:S70–3.View ArticlePubMedGoogle Scholar
- Levi M, van der Poll T, Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med. 2012;70:114–20.PubMedGoogle Scholar
- Schmidt EP, Li G, Li L, Fu L, Yang Y, Overdier KH, et al. The circulating glycosaminoglycan signature of respiratory failure in critically ill adults. J Biol Chem. 2014;289:8194–202.View ArticlePubMedGoogle Scholar
- Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105:3910–7.View ArticlePubMedGoogle Scholar
- Redl H, Schlag G, Schiesser A, Davies J. Thrombomodulin release in baboon sepsis: its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor. J Infect Dis. 1995;171:1522–7.View ArticlePubMedGoogle Scholar
- Boehme MW, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology. 1996;87:134–40.PubMed CentralPubMedGoogle Scholar
- Lin SM, Wang YM, Lin HC, Lee KY, Huang CD, Liu CY, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med. 2008;36:683–9.View ArticlePubMedGoogle Scholar
- Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115:1267–74.View ArticlePubMed CentralPubMedGoogle Scholar
- Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.View ArticlePubMedGoogle Scholar
- Levi M. The coagulant response in sepsis. Clin Chest Med. 2008;29:627–42.View ArticlePubMedGoogle Scholar
- Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 1989;264:10396–401.PubMedGoogle Scholar
- Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84:398–405.View ArticlePubMedGoogle Scholar
- Koyama K, Madoiwa S, Nunomiya S, Koinuma T, Wada M, Sakata A, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care. 2014;18:R13.View ArticlePubMed CentralPubMedGoogle Scholar
- Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res. 2009;124:608–13.View ArticlePubMedGoogle Scholar
- Palmer L, Martin L. Traumatic coagulopathy–part 1: pathophysiology and diagnosis. J Vet Emerg Crit Care. 2014;24:63–74.View ArticleGoogle Scholar
- Matthay MA. Severe sepsis–a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 2001;344:759–62.View ArticlePubMedGoogle Scholar
- Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365–76.View ArticlePubMedGoogle Scholar
- Dokai M, Madoiwa S, Yasumoto A, Kashiwakura Y, Ishiwata A, Sakata A, et al. Local regulation of neutrophil elastase activity by endogenous alpha1-antitrypsin in lipopolysaccharide-primed hematological cells. Thromb Res. 2011;128:283–92.View ArticlePubMedGoogle Scholar
- Moir E, Robbie LA, Bennett B, Booth NA. Polymorphonuclear leucocytes have two opposing roles in fibrinolysis. Thromb Haemost. 2002;87:1006–10.PubMedGoogle Scholar
- Wu K, Urano T, Ihara H, Takada Y, Fujie M, Shikimori M, et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood. 1995;86:1056–61.PubMedGoogle Scholar
- Bach-Gansmo ET, Halvorsen S, Godal HC, Skjonsberg OH. Impaired clot lysis in the presence of human neutrophil elastase. Thromb Res. 1995;80:153–9.View ArticlePubMedGoogle Scholar
- Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.View ArticlePubMedGoogle Scholar
- Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107:528–34.View ArticlePubMedGoogle Scholar
- Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15:1318–21.View ArticlePubMed CentralPubMedGoogle Scholar
- Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191:677–91.View ArticlePubMed CentralPubMedGoogle Scholar
- Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107:15880–5.View ArticlePubMed CentralPubMedGoogle Scholar
- Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16:887–96.View ArticlePubMedGoogle Scholar
- Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765–77.View ArticlePubMedGoogle Scholar
- Kohno I, Inuzuka K, Itoh Y, Nakahara K, Eguchi Y, Sugo T, et al. A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin: its application to the measurement of granulocyte-derived elastase digests in plasma. Blood. 2000;95:1721–8.PubMedGoogle Scholar
- Gando S, Hayakawa M, Sawamura A, Hoshino H, Oshiro A, Kubota N, et al. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation. Thromb Res. 2007;121:67–73.View ArticlePubMedGoogle Scholar
- Sterrenberg L, Gravesen M, Haverkate F, Nieuwenhuizen W. Granulocyte enzyme mediated degradation of human fibrinogen in plasma in vitro. Thromb Res. 1983;31:719–28.View ArticlePubMedGoogle Scholar
- Madoiwa S, Tanaka H, Nagahama Y, Dokai M, Kashiwakura Y, Ishiwata A, et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res. 2011;127:349–55.View ArticlePubMedGoogle Scholar
- Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, Noguchi T. Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009;58:198–203.View ArticlePubMedGoogle Scholar
- King EG, Bauza GJ, Mella JR, Remick DG. Pathophysiologic mechanisms in septic shock. Lab Invest. 2014;94:4–12.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.